Groundbreaking cancer drug enters first human trials
NCT ID NCT06959706
Summary
This is the first study in humans testing a new cancer drug called TGW101. Researchers will give the drug to 50 patients with advanced solid tumors to check if it's safe and to find the right dose. They'll also look for early signs that the drug might help shrink tumors in cancers like breast, lung, prostate, and ovarian cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Honor Health
RECRUITINGScottsdale, Arizona, 85258, United States
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
-
NEXT Dallas
RECRUITINGIrving, Texas, 75039, United States
-
NEXT San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.